Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pear Therapeutics, Inc. (PEAR)

0.2646   -0.071 (-21.04%) 03-22 15:02
Open: 0.3 Pre. Close: 0.3351
High: 0.3117 Low: 0.2645
Volume: 1,433,860 Market Cap: 56(M)

Technical analysis

as of: 2023-03-22 2:50:07 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.94     One year: 1.37
Support: Support1: 0.2    Support2: 0.16
Resistance: Resistance1: 0.8    Resistance2: 1.17
Pivot: 0.64
Moving Average: MA(5): 0.36     MA(20): 0.73
MA(100): 1.43     MA(250): 2.24
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 8.7     %D(3): 9.3
RSI: RSI(14): 23.2
52-week: High: 6.73  Low: 0.2
Average Vol(K): 3-Month: 597 (K)  10-Days: 2,547 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PEAR ] has closed above bottom band by 13.8%. Bollinger Bands are 64.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.48 - 0.48 0.48 - 0.49
Low: 0.25 - 0.25 0.25 - 0.25
Close: 0.33 - 0.34 0.34 - 0.34

Company Description

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Headline News

Wed, 22 Mar 2023
Pear Therapeutics Inc (PEAR) Stock Falls -50.00% This Week: Is It a Good Pick? - InvestorsObserver

Wed, 22 Mar 2023
Why GameStop Shares Are Trading Higher By Around 44%; Here ... - UK

Tue, 21 Mar 2023
Why Is Pear Therapeutics (PEAR) Stock Up 21% Today? - InvestorPlace

Mon, 20 Mar 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... -

Mon, 20 Mar 2023
PEAR stock extends selloff as downgrades follow strategic shake-up ... - Seeking Alpha

Sun, 19 Mar 2023
Pear Therapeutics' Cuts Are Not Enough; 'Strategic Alternatives' Among Next Steps - MedCity News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Health Information Services
Shares Out. 0 (M)
Shares Float 140 (M)
% Held by Insiders 3.653e+007 (%)
% Held by Institutions 16.8 (%)
Shares Short 1,660 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.2342e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) -265.3
Operating Margin (%) -1
Return on Assets (ttm) 109.6
Return on Equity (ttm) -76.7
Qtrly Rev. Growth 1.145e+007
Gross Profit (p.s.) 0.05
Sales Per Share 0.02
EBITDA (p.s.) -0.78
Qtrly Earnings Growth -0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -129 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 12.97
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 1.7e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.